drug · small molecule
bempedoic acid
Marketedupdated 3mo agoby $ESPR Esperion Therapeutics, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.
indications
investigational
Hyperlipidemia
targets
ATP-citrate synthase
all catalysts(9)
approval · 9
Feb 21, 2020
approval
$ESPR
NEXLETOL (BEMPEDOIC ACID) — FDA approval
bempedoic acid
→
Sep 20, 2023
approval
$ESPR
NEXLETOL (BEMPEDOIC ACID) — FDA approval
bempedoic acid
→
Dec 13, 2023
approval
$ESPR
NEXLETOL (BEMPEDOIC ACID) — FDA approval
bempedoic acid
→
Mar 22, 2024
approval
$ESPR
NEXLETOL (BEMPEDOIC ACID) — FDA approval
bempedoic acid
→
Mar 22, 2024
approval
$ESPR
NEXLETOL (BEMPEDOIC ACID) — FDA approval
bempedoic acid
→
Jul 21, 2025
approval
$ESPR
NEXLETOL (BEMPEDOIC ACID) — FDA approval
bempedoic acid
→
Jul 21, 2025
approval
$ESPR
NEXLETOL (BEMPEDOIC ACID) — FDA approval
bempedoic acid
→
Nov 21, 2025
approval
$ESPR
NEXLETOL (BEMPEDOIC ACID) — FDA approval
bempedoic acid
→
Jan 9, 2026
approval
$ESPR
NEXLETOL (BEMPEDOIC ACID) — FDA approval
bempedoic acid
→
Trials studying bempedoic acid
- —A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
- phase3A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid
- —A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
- phase3A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
- —Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
- phase1Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin
- phase3A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 22, 2027
219 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Jun 19, 2040compositionUS 11613511
- Jun 19, 2040formulationUS 11760714
- Jun 19, 2040method-of-use (U-3873)US 11926584
- Jun 19, 2040compositionUS 12398087
- Jun 19, 2040compositionUS 12404227
- Mar 14, 2036method-of-use (U-3883)US 11744816
- Dec 3, 2030compositionUS 73357994.3y
FDA exclusivities (2)
- Mar 22, 2027I-943Indication (3y)219d
- Mar 22, 2027I-944Indication (3y)219d
News(2)
- Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the massesThe CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.biopharma_dive · 4d ago
- Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorMerck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.biospace · 29d ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that